Actualités

La Pologne : Où peut-on injecter ? La campagne « Room for change »

30 décembre 2015

La discussion publique sur les réductions des risques en Pologne est figée dans les années 1990s. Lisez ce qui peut être fait pour sauver des vies et pour réduire les coûts des traitements des usagers de drogues, en termes de la réalité décrite par des experts des politiques des drogues polonaises. Pour en savoir plus, en anglais, veuillez lire les informations ci-dessous.

Abonnez-vous à l'Alerte mensuelle de l'IDPC pour recevoir des informations relatives à la politique des drogues.

By Agnieszka Sieniawska

Around the world, the discussion surrounding the need to broaden access to harm-reduction programs is reaching ever greater numbers of people. In Western countries, this approach is a priority in dealing with drug use. Flagship harm-reduction programs, such as needle and syringe exchanges, substitution therapy, and safe injection rooms, are used in the majority of European countries, in order to prevent transmission of blood-borne diseases, improve the health of people living with addiction to psychoactive substance, increase safety in cities, and reduce related criminal behavior.

Watch the Polish Drug Policy Network & Drugreporters joint video on the Polish situation:

The experience of those countries, linked to public demand for safer streets, and a growing number of people seeking treatment, is what made them pursue harm reduction, including the reduction of crime associated with drug-use. The best example is the Swiss model, where a pilot program introduced medicinal heroin treatment for people with opiate addiction. Just a few years later, a significant improvement in the health of the patients was evident; criminal behavior by addicts plunged (from 90 percent to 10 percent), while the operation of the clinics cost the state significantly less than the costs related to treatment with ineffective methods, or isolation of heroin users in prisons.

Click here to read the full article.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.